Metadata
| Source Table | grants |
| Source ID | Z8dWZHr-BZ |
| Description | to Eiger InnoTherapeutics, USD 3000000, 2024-04 |
| Source URL | coefficientgiving.org/funds/ |
| Parent | Coefficient Giving |
| Children | — |
| Created | Mar 12, 2026, 5:54 AM |
| Updated | Mar 22, 2026, 2:59 AM |
| Synced | Mar 19, 2026, 8:57 PM |
Record Data
id | Z8dWZHr-BZ |
organizationId | Coefficient Giving(organization) |
granteeId | Eiger InnoTherapeutics |
orgEntityId | Coefficient Giving(organization) |
orgDisplayName | — |
granteeEntityId | — |
granteeDisplayName | Eiger InnoTherapeutics |
name | Eiger InnoTherapeutics — Lonafarnib and Pegylated Interferon Lambda |
amount | 3000000 |
currency | USD |
period | — |
date | 2024-04 |
status | — |
source | coefficientgiving.org/funds/ |
notes | [Scientific Research] Open Philanthropy recommended an investment of $3,000,000 in Eiger InnoTherapeutics, a new company founded by Professor Jeffrey S. Glenn, that has acquired the rights to two drugs, lonafarnib and pegylated interferon lambda. The company will develop Lonafarnib for use against h… |
programId | B4pZkOtjSk |
dataSourceId | — |
Source Check Verdicts
confirmed95% confidence
Last checked: 4/9/2026
[deterministic-row-match] Deterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Debug info
Thing ID: Z8dWZHr-BZ
Source Table: grants
Source ID: Z8dWZHr-BZ
Parent Thing ID: sid_ULjDXpSLCI